Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Live updates

1. 1h ago

   Telix acquires ITM to expand radiopharmaceutical footprint

   Telix is acquiring Germany-based radioisotope maker ITM to establish a radiopharmaceutical powerhouse. While some reports value the deal at $1.6B or $1.65B, other sources state the merger is worth up to $2.35B. Analysts express extreme bullishness regarding the move, which positions Telix to compete in territory previously dominated by Novartis. The merger follows a surprise FDA rejection received by one of the involved companies.

   Why it matters

   Radiopharmaceuticals combine targeted molecules with radioactive isotopes to treat or image diseases. This acquisition allows Telix to secure its isotope supply chain and expand its global reach.

   What is confirmed

   • Telix is acquiring Germany's ITM Isotope.
   • The acquisition aims to create a radiopharmaceutical powerhouse.

   Still unconfirmed

   • The deal is valued at $1.6B.
   • The deal is valued at $1.65B.
   • The merger is worth up to $2.35B.
   • Analysts are extremely bullish on the acquisition.
   • The merger occurred after one company received a surprise FDA rejection.

   What to watch next

   • Confirmation of the final transaction value
   • FDA regulatory updates for the combined entity's pipeline
   Sources used for this update (6)

   1. statnews.com — Radiopharma companies merge after one receives surprise FDA rejection
   2. Fierce Biotech — Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
   3. Investor's Business Daily — Why This Biotech Crashed On Its Proposed $2.35 Billion Merger
   4. Endpoints News — Telix and radioisotope maker ITM merge in deal worth up to $2.35B
   5. BioPharma Dive — Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
   6. Seeking Alpha — Telix to buy Germany’s ITM Isotope for $1.65B to expand radiopharma footprint (TLX:NASDAQ)
   confidence 70%